뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - diclofenamide 50mg - tablet - 50 mg - active: diclofenamide 50mg

영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

imported (italy) - diclofenamide - oral tablet - 50mg

영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

imported (united states) - diclofenamide - oral tablet - 50mg

아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

merck sharp and dohme limited - diclofenamide - tablets - 50 milligram

미국 - 영어 - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, inc. - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium 50 mg - carefully consider the potential benefits and risks of diclofenac and other treatment options before deciding to use diclofenac sodium delayed-release tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). diclofenac is indicated: - for relief of signs and symptoms of osteoarthritis - for relief of signs and symptoms of rheumatoid arthritis - for acute or long-term use in the relief of signs and symptoms of ankylosing spondylitis diclofenac sodium delayed-release tablets are contraindicated in patients with known hypersensitivity to diclofenac. diclofenac should not be given to patients who have experienced asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients (see warnings, anaphylactoid reactions , and precautions, preexisting asthma ). diclofenac are contraindicated for the treatment of peri-operati

캐나다 - 영어 - Health Canada

pharma stulln inc. - diclofenac sodium - solution - 0.1% - diclofenac sodium 0.1% - antiallergic agents